Scorpius Holdings Announces Partnership with U.S. Biotech Company
Scorpius Holdings, Inc (NYSE American: SCPX) has announced a strategic partnership with a U.S.-based biotech company. The agreement involves the biotech company working with Scorpius' program management team and plans to transfer a research cell bank (RCB) to Scorpius' facilities in San Antonio, TX for future biomanufacturing activities.
CEO Jeff Wolf emphasized that this partnership demonstrates Scorpius' ability to support biotech companies throughout their development journey. He noted a growing trend of biotech companies seeking U.S.-based biomanufacturing partners, highlighting Scorpius' capabilities in early-stage development, preclinical manufacturing, and cGMP clinical manufacturing for both mammalian and microbial programs.
Wolf also highlighted Scorpius' flexibility and responsiveness as key advantages, addressing the critical need for secure, U.S.-based development and manufacturing support for biologics research.
Scorpius Holdings, Inc (NYSE American: SCPX) ha annunciato una partnership strategica con una società biotecnologica con sede negli Stati Uniti. L'accordo prevede che la società biotecnologica collabori con il team di gestione dei programmi di Scorpius e prevede il trasferimento di una banca cellulare di ricerca (RCB) nelle strutture di Scorpius a San Antonio, TX, per future attività di biomanifattura.
Il CEO Jeff Wolf ha sottolineato che questa partnership dimostra la capacità di Scorpius di supportare le aziende biotecnologiche durante il loro percorso di sviluppo. Ha notato una crescente tendenza delle aziende biotecnologiche a cercare partner di biomanifattura con sede negli Stati Uniti, evidenziando le capacità di Scorpius nello sviluppo iniziale, nella produzione preclinica e nella produzione clinica cGMP sia per programmi mammiferi che microbici.
Wolf ha anche evidenziato la flessibilità e la reattività di Scorpius come vantaggi chiave, affrontando l'esigenza critica di supporto sicuro per lo sviluppo e la produzione di ricerche biologiche con sede negli Stati Uniti.
Scorpius Holdings, Inc (NYSE American: SCPX) ha anunciado una asociación estratégica con una empresa biotecnológica con sede en EE. UU.. El acuerdo implica que la empresa biotecnológica trabajará con el equipo de gestión de programas de Scorpius y planea transferir un banco celular de investigación (RCB) a las instalaciones de Scorpius en San Antonio, TX, para futuras actividades de biomanufactura.
El CEO Jeff Wolf destacó que esta asociación demuestra la capacidad de Scorpius para apoyar a las empresas biotecnológicas a lo largo de su proceso de desarrollo. Señaló una tendencia creciente de las empresas biotecnológicas que buscan socios de biomanufactura en EE. UU., destacando las capacidades de Scorpius en desarrollo en etapas tempranas, producción preclínica y producción clínica cGMP tanto para programas de mamíferos como microbianos.
Wolf también subrayó la flexibilidad y capacidad de respuesta de Scorpius como ventajas clave, abordando la necesidad crítica de un apoyo seguro para el desarrollo y la fabricación de investigación biológica con sede en EE. UU.
Scorpius Holdings, Inc (NYSE American: SCPX)는 미국에 본사를 둔 생명공학 회사와의 전략적 파트너십을 발표했습니다. 이 계약은 생명공학 회사가 Scorpius의 프로그램 관리팀과 협력하고 자 연구 세포은행(RCB)을 Scorpius의 시설인 텍사스주 샌안토니오에 이전하여 향후 생물 제조 활동을 위한 계획을 포함합니다.
CEO Jeff Wolf는 이 파트너십이 Scorpius가 생명공학 회사를 개발 과정 전반에 걸쳐 지원할 수 있는 능력을 보여준다고 강조했습니다. 그는 미국에 본사를 둔 생물 제조 파트너를 찾는 생명공학 회사의 증가하는 추세를 언급했으며, Scorpius의 초기 단계 개발, 임상 전 제조 및 cGMP 임상 제조 능력을 강조했습니다.
Wolf는 또한 Scorpius의 유연성과 신속한 대응이 주요 장점이라고 강조하며, 생물학적 연구를 위한 안전한 미국 내 개발 및 제조 지원의 중요한 필요성을 다루었습니다.
Scorpius Holdings, Inc (NYSE American: SCPX) a annoncé un partenariat stratégique avec une entreprise biotechnologique basée aux États-Unis. L'accord implique que l'entreprise biotechnologique collabore avec l'équipe de gestion des programmes de Scorpius et prévoit de transférer une banque de cellules de recherche (RCB) dans les installations de Scorpius à San Antonio, TX, pour de futures activités de biomanufacture.
Le PDG Jeff Wolf a souligné que ce partenariat démontre la capacité de Scorpius à soutenir les entreprises biotechnologiques tout au long de leur parcours de développement. Il a noté une tendance croissante des entreprises biotechnologiques à rechercher des partenaires de biomanufacture basés aux États-Unis, mettant en avant les capacités de Scorpius dans le développement précoce, la fabrication préclinique et la fabrication clinique cGMP pour des programmes à la fois mammifères et microbiens.
Wolf a également souligné la flexibilité et la réactivité de Scorpius comme des avantages clés, répondant à la nécessité critique d'un soutien sécurisé pour le développement et la fabrication de recherches biologiques basées aux États-Unis.
Scorpius Holdings, Inc (NYSE American: SCPX) hat eine strategische Partnerschaft mit einem in den USA ansässigen Biotechnologieunternehmen angekündigt. Die Vereinbarung sieht vor, dass das Biotechnologieunternehmen mit dem Programmmanagement-Team von Scorpius zusammenarbeitet und plant, eine Forschungszellbank (RCB) in die Einrichtungen von Scorpius in San Antonio, TX, zu übertragen, um zukünftige Bioproduktionsaktivitäten durchzuführen.
CEO Jeff Wolf betonte, dass diese Partnerschaft die Fähigkeit von Scorpius zeigt, Biotechnologieunternehmen während ihrer Entwicklungsreise zu unterstützen. Er bemerkte einen wachsenden Trend von Biotechnologieunternehmen, die nach Bioproduktionspartnern mit Sitz in den USA suchen, und hob die Fähigkeiten von Scorpius in der frühen Entwicklungsphase, der präklinischen Herstellung und der cGMP- klinischen Herstellung sowohl für säugetier- als auch mikrobiellen Programme hervor.
Wolf hob auch die Flexibilität und Reaktionsschnelligkeit von Scorpius als wichtige Vorteile hervor und sprach das kritische Bedürfnis nach sicherer, in den USA ansässiger Unterstützung für Entwicklung und Herstellung von biologischen Forschungen an.
- Strategic partnership with a U.S.-based biotech company
- Potential for future biomanufacturing activities
- Demonstrates capability to support biotech companies at various stages
- Growing demand for U.S.-based biomanufacturing partners
- Flexibility and responsiveness highlighted as competitive advantages
- None.
Insights
This partnership marks a significant step for Scorpius Holdings in solidifying its position in the U.S. biomanufacturing landscape. The agreement to potentially transfer a research cell bank (RCB) to Scorpius' facilities indicates a high level of trust from the unnamed biotech partner. This could lead to future revenue streams if the partnership progresses to clinical manufacturing stages.
The emphasis on U.S.-based manufacturing aligns with the growing trend of "onshoring" in the biotech industry, driven by supply chain concerns and regulatory preferences. Scorpius' ability to offer end-to-end services from early-stage development to cGMP clinical manufacturing for both mammalian and microbial programs positions them well in a competitive market.
However, the lack of specific financial details or timelines in this announcement limits the immediate assessment of its impact on Scorpius' bottom line. Investors should monitor for future updates on the progression of this partnership and any resulting manufacturing contracts.
This partnership announcement, while positive, should be viewed with cautious optimism. The biotech sector is highly competitive and partnerships at early stages don't always translate to long-term revenue. However, Scorpius' focus on flexibility and responsiveness could be a key differentiator in attracting smaller biotech clients who may feel overlooked by larger CDMOs.
The company's strategic positioning in the U.S. market taps into the current geopolitical climate favoring domestic production. This could potentially lead to increased demand for Scorpius' services, especially if government initiatives continue to support U.S.-based manufacturing.
Investors should consider Scorpius' capacity utilization rates and client diversification in future reports to gauge the company's growth trajectory and risk profile. The ability to convert early-stage partnerships into full-scale manufacturing contracts will be important for long-term success in this capital-intensive industry.
Agreement reinforces Scorpius' position as a respected U.S. biomanufacturing partner for early-stage and clinical development
DURHAM, N.C., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or the “Company”), an integrated biomanufacturing company, today announced a strategic partnership with a U.S.-based biotech company. Under this agreement, the biotech company will work with Scorpius' program management team, with plans to transfer a research cell bank (RCB) to Scorpius’ state-of-the-art facilities in San Antonio, TX for future biomanufacturing activities.
“This partnership underscores Scorpius' ability to support biotech companies at every stage of their journey, from innovative research to clinical trials,” said Jeff Wolf, CEO of Scorpius. “We are seeing a growing number of biotech companies seeking U.S.-based biomanufacturing partners, and Scorpius is equipped to provide early-stage development, preclinical manufacturing, and cGMP clinical manufacturing for both mammalian and microbial programs.”
Wolf added, “Our clients highlight our flexibility and responsiveness—qualities often lacking in larger multinational CDMOs. With this partnership, we continue to fulfill the critical need for secure, U.S.-based development and manufacturing support for groundbreaking biologics research.”
Scorpius Holdings, Inc.
Scorpius Holdings, Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, TX. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, please visit www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements such as the biotech company working with Scorpius' program management team, with plans to transfer a research cell bank (RCB) to Scorpius’ state-of-the-art facilities in San Antonio, TX for future biomanufacturing activities; and continuing to fulfill the critical need for secure, U.S.-based development and manufacturing support for groundbreaking biologics research with this partnership. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of the Company to derive the anticipated benefits from the partnership including expanding the services to be provided the Company’s ability to expand its large molecule biomanufacturing CDMO services, attract new customers, profit from its pipeline and continue to grow revenue; the ability to capture a meaningful market share; the ability to generate meaningful cash flow and become cash flow positive; the Company’s financing needs, its cash balance being sufficient to sustain operations and its ability to raise capital when needed, the Company’s ability to leverage fixed costs and achieve long-term profitability; the Company’s ability to obtain regulatory approvals or to comply with ongoing regulatory requirements, regulatory limitations relating to the Company’s ability to successfully promote its services and compete as a pure- play CDMO, and other factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, subsequent quarterly reports on Form 10-Qs and any other filings the Company makes with the SEC. The information in this presentation is provided only as of the date presented, and the Company undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
ir@scorpiusbiologics.com
FAQ
What is the new partnership announced by Scorpius Holdings (SCPX)?
What capabilities does Scorpius Holdings (SCPX) offer to biotech companies?
Where are Scorpius Holdings' (SCPX) biomanufacturing facilities located?
What advantages does Scorpius Holdings (SCPX) claim over larger CDMOs?
